PDS Biotech Announces Positive Clinical Trial Data

PDS Biotech has announced positive interim Phase 2 clinical trial data for its PDS01ADC therapy in metastatic colorectal cancer. The trial, led by the National Cancer Institute, showed a 78% objective response rate (ORR) with PDS01ADC, significantly higher than the 35% ORR in a parallel trial without the therapy. Furthermore, the 2-year survival rate exceeded 80% for patients treated with PDS01ADC, indicating promising therapeutic potential.